Sell Sprint!: Again...
Health Care: Drugs
Human Genome Sciences Inc (HGSI: NASDAQ)
$9.97 -0.22 | -2.15%
02/08/12 - 01:15 PM ET
5.09M / 6.24M
Vol / Avg. Vol:10.16 / 10.19
Open / Prev. Close:9.76 - 10.27
Today's Range:6.51 - 30.15
52 Wk Range:37.89%
Performance YTD:TheStreet Rating:
Portfolios with HGSI
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- ContributorUnder-$10 Setting Up To Tra...
- Userdividend stocks and penny s...
- UserNick
- ContributorEarnings Short Squeeze Play...
- UserTop Ten Stock Picks by Core...
- UserLong Term Stock Picks by Co...
- ContributorEarnings Short Squeeze Play...
- Contributor5 Biotech Drug-Launch Stock...
- Userpossible investments
Latest HGSI Headlines from TheStreet
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Set to Trigger Big Moves 01.09.12 | 12:01 pm
- The Next Big Thing In Biotech: 2012 Outlook
01.06.12 | 05:01 am - Dendreon: Provenge Q4 Sales Beat 01.05.12 | 10:01 am
- Human Genome Stock Hits New 52-Week Low (HGSI) 12.15.11 | 04:12 pm
- Human Genome Sciences Inc (HGSI): Today's Featured Drugs Winner 12.08.11 | 04:12 pm
- Best Biotech CEO of 2011 -- Vote Here 12.06.11 | 06:12 am
- Human Genome Sciences Stock Hits New 52-Week Low (HGSI) 11.22.11 | 02:11 pm
- Human Genome Sciences Stock Hits New 52-Week Low (HGSI) 11.14.11 | 01:11 pm
- Stocks Under $10: Value Biotech Stock 11.08.11 | 02:11 pm
Press Releases for HGSI
- Human Genome Sciences Reports Progress With Commercialization Of BENLYSTA® And Announces 2012 Goals At JPMorgan Healthcare Conference - Business Wire 01.09.12 | 07:01 am
- Human Genome Sciences Invites Investors To Listen To Webcast Of Presentation At J.P. Morgan Healthcare Conference - Business Wire 01.05.12 | 04:01 pm
- Human Genome Sciences And GlaxoSmithKline Initiate Phase 3 Trial Of Belimumab (BENLYSTA®) Administered Subcutaneously In Subjects With Systemic Lupus Erythematosus - Business Wire 12.15.11 | 07:12 am
- Human Genome Sciences Invites Investors To Listen To Webcast Of Presentation At Deutsche Bank Conference - Business Wire 12.01.11 | 04:12 pm
- Human Genome Sciences Invites Investors To Listen To Webcast Of Presentation At Piper Jaffray Conference - Business Wire 11.28.11 | 04:11 pm
- Rigrodsky & Long, P.A. Announces Class Action Lawsuit Against Human Genome Sciences, Inc. - Business Wire 11.15.11 | 06:11 pm
- Human Genome Sciences Invites Investors To Listen To Webcast Of Presentation At Credit Suisse Conference - Business Wire 11.07.11 | 04:11 pm
- Human Genome Sciences Completes Offering Of $494.5 Million Of Convertible Senior Notes - Business Wire 11.07.11 | 12:11 pm
- Human Genome Sciences Announces Multiple Abstracts Related To BENLYSTA® And Systemic Lupus Erythematosus To Be Presented At The 2011 ACR/ARHP Annual Scientific Meeting - Business Wire 11.04.11 | 07:11 am
- Human Genome Sciences Announces Exercise Of Option To Purchase Additional Notes For Total Convertible Notes Issuance Of $494.5 Million - Business Wire 11.03.11 | 07:11 am
Partner Headlines for HGSI
- Stocks To Watch Week Of Feb. 6 - Seeking Alpha 02.06.12 | 08:02 am
- Biopharma Stocks To Watch This Week - Seeking Alpha 01.19.12 | 09:01 am
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
- Analyzing 5 Biotech Stocks And Their Takeover Potential - Seeking Alpha 01.13.12 | 08:01 am
- Short Covering Sparks HGSI Price Spike - Seeking Alpha 01.12.12 | 09:01 am
- Stocks To Watch This Week - Seeking Alpha 01.10.12 | 08:01 am
- Biotech Investors Buoyed By Signs Of Speedier Drug Launches - Seeking Alpha 01.09.12 | 08:01 am
- Benzinga's M&A Chatter for Friday January 6, 2012 - Benzinga 01.06.12 | 04:01 pm
- Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo - Press Releases - Zacks 12.29.11 | 09:12 am
- Goldman Sachs Maintains Neutral on Human Genome Sciences Despite Weakened Benlysta Sales - Benzinga 12.29.11 | 09:12 am
